Quick Answer
Tenaya Therapeutics, Inc. reported Net Income of -$90.60 million for fiscal year 2025.
Tenaya Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$90.60M | +18.5% |
| 2024 | -$111.13M | +10.4% |
| 2023 | -$124.08M | -0.3% |
| 2022 | -$123.67M | -70.1% |
| 2021 | -$72.72M | -89.4% |
| 2020 | -$38.40M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.27M | +20.9% | +12.9% |
| June 30, 2025 | -$23.28M | +20.9% | +13.3% |
| March 31, 2025 | -$26.86M | +16.6% | -4.8% |
| September 30, 2024 | -$25.63M | +12.0% | +12.9% |
| June 30, 2024 | -$29.43M | +11.5% | +8.7% |
| March 31, 2024 | -$32.23M | -1.5% | -10.6% |
| September 30, 2023 | -$29.14M | +5.1% | +12.4% |
| June 30, 2023 | -$33.27M | -17.2% | -4.8% |
- Tenaya Therapeutics, Inc. showed an increase of +18.5% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Tenaya Therapeutics, Inc.’s net income has declined by 136.0% (from -$38.40 million to -$90.60 million).
- The most recent figure is from Tenaya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: